{"transactions":[{"id":2565317,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":135379,"kind":"person","name":"Jones Aranthan II","position":1,"cik":"0001785894","reported_name":"Jones Aranthan II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-09-17T12:52:04.000Z","date":"2021-09-15","kind":"exercise","acquired":false,"shares":7842,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested with respect to 25% of the underlying shares on February 26, 2021, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person remains continuously employed by the Issuer through the applicable vesting date."}],"balance_after":47158,"derivative":{"exercise_price":11.32,"expiration_date":"2030-02-25","underlying":"Common Stock","underlying_shares":7842},"source":{"system":"sec-edgar","filing":"0001209191-21-056530","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919121056530/doc4.xml","form_type":"4"}},{"id":2565316,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":135379,"kind":"person","name":"Jones Aranthan II","position":1,"cik":"0001785894","reported_name":"Jones Aranthan II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-09-17T12:52:04.000Z","date":"2021-09-15","kind":"exercise","acquired":false,"shares":4277,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested with respect to 25% of the underlying shares on July 25, 2020, with the remaining 75% of the shares vesting in 36 equal monthly installments beginning August 25, 2020, provided the Reporting Person remains continuously employed by the Issuer through each monthly vesting date."}],"balance_after":33224,"derivative":{"exercise_price":12.27,"expiration_date":"2029-07-24","underlying":"Common Stock","underlying_shares":4277},"source":{"system":"sec-edgar","filing":"0001209191-21-056530","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919121056530/doc4.xml","form_type":"4"}},{"id":2565315,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":135379,"kind":"person","name":"Jones Aranthan II","position":1,"cik":"0001785894","reported_name":"Jones Aranthan II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2021-09-17T12:52:04.000Z","date":"2021-09-15","kind":"sale","acquired":false,"shares":16824,"price":16.488,"value":277394.112,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"A portion of the shares was sold to satisfy the exercise price and tax obligations relating to the acquisition of the shares in connection with the stock option exercise."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.40 to $16.605, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":81980,"source":{"system":"sec-edgar","filing":"0001209191-21-056530","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919121056530/doc4.xml","form_type":"4"}},{"id":2565314,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":135379,"kind":"person","name":"Jones Aranthan II","position":1,"cik":"0001785894","reported_name":"Jones Aranthan II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2021-09-17T12:52:04.000Z","date":"2021-09-15","kind":"exercise","acquired":true,"shares":7842,"price":11.32,"value":88771.44,"ownership":{"direct":true},"balance_after":98804,"source":{"system":"sec-edgar","filing":"0001209191-21-056530","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919121056530/doc4.xml","form_type":"4"}},{"id":2565313,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":135379,"kind":"person","name":"Jones Aranthan II","position":1,"cik":"0001785894","reported_name":"Jones Aranthan II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2021-09-17T12:52:04.000Z","date":"2021-09-15","kind":"exercise","acquired":true,"shares":4277,"price":12.27,"value":52478.79,"ownership":{"direct":true},"balance_after":90962,"source":{"system":"sec-edgar","filing":"0001209191-21-056530","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919121056530/doc4.xml","form_type":"4"}},{"id":2623683,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":135379,"kind":"person","name":"Jones Aranthan II","position":1,"cik":"0001785894","reported_name":"Jones Aranthan II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2021-07-27T20:37:01.000Z","date":"2021-07-26","kind":"sale","acquired":false,"shares":7250,"price":19.6933,"value":142776.425,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.61 to $19.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":86685,"source":{"system":"sec-edgar","filing":"0001209191-21-048276","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919121048276/doc4.xml","form_type":"4"}},{"id":2785705,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":135379,"kind":"person","name":"Jones Aranthan II","position":1,"cik":"0001785894","reported_name":"Jones Aranthan II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-03-16T20:20:29.000Z","date":"2021-03-15","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested with respect to 25% of the underlying shares on February 26, 2021, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date"}],"balance_after":55000,"derivative":{"exercise_price":11.32,"expiration_date":"2030-02-25","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-020782","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919121020782/doc4.xml","form_type":"4"}},{"id":2785704,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":135379,"kind":"person","name":"Jones Aranthan II","position":1,"cik":"0001785894","reported_name":"Jones Aranthan II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2021-03-16T20:20:29.000Z","date":"2021-03-15","kind":"sale","acquired":false,"shares":18000,"price":17.7228,"value":319010.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"A portion of the shares were sold to satisfy the exercise price and tax obligations relating to the acquisition of the shares in connection with the stock option exercise."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.69 to $17.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":93935,"source":{"system":"sec-edgar","filing":"0001209191-21-020782","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919121020782/doc4.xml","form_type":"4"}},{"id":2785703,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":135379,"kind":"person","name":"Jones Aranthan II","position":1,"cik":"0001785894","reported_name":"Jones Aranthan II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2021-03-16T20:20:29.000Z","date":"2021-03-15","kind":"exercise","acquired":true,"shares":15000,"price":11.32,"value":169800.0,"ownership":{"direct":true},"balance_after":111935,"source":{"system":"sec-edgar","filing":"0001209191-21-020782","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919121020782/doc4.xml","form_type":"4"}},{"id":2812033,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":135379,"kind":"person","name":"Jones Aranthan II","position":1,"cik":"0001785894","reported_name":"Jones Aranthan II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2021-03-03T23:40:20.000Z","date":"2021-03-02","kind":"sale","acquired":false,"shares":3865,"price":18.0381,"value":69717.2565,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.145, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":96935,"source":{"system":"sec-edgar","filing":"0001209191-21-017273","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919121017273/doc4.xml","form_type":"4"}},{"id":2829199,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":135379,"kind":"person","name":"Jones Aranthan II","position":1,"cik":"0001785894","reported_name":"Jones Aranthan II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-02-26T22:17:02.000Z","date":"2021-02-24","kind":"exercise","acquired":false,"shares":22499,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vested and became exercisable with respect to 25% of the shares subject to the option on July 25, 2020, and the remaining 75% of the shares vests in 36 equal monthly installments beginning August 25, 2020, provided the Reporting Person remains continuously employed by the issuer through each monthly vesting date."}],"balance_after":37501,"derivative":{"exercise_price":12.27,"expiration_date":"2029-07-24","underlying":"Common Stock","underlying_shares":22499},"source":{"system":"sec-edgar","filing":"0001209191-21-014873","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919121014873/doc4.xml","form_type":"4"}},{"id":2829198,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":135379,"kind":"person","name":"Jones Aranthan II","position":1,"cik":"0001785894","reported_name":"Jones Aranthan II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-02-26T22:17:02.000Z","date":"2021-02-24","kind":"grant","acquired":true,"shares":61200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests with respect to 25% of the underlying shares on February 24, 2022, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date."}],"balance_after":61200,"derivative":{"exercise_price":20.28,"expiration_date":"2031-02-23","underlying":"Common Stock","underlying_shares":61200},"source":{"system":"sec-edgar","filing":"0001209191-21-014873","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919121014873/doc4.xml","form_type":"4"}},{"id":2829197,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":135379,"kind":"person","name":"Jones Aranthan II","position":1,"cik":"0001785894","reported_name":"Jones Aranthan II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2021-02-26T22:17:02.000Z","date":"2021-02-24","kind":"sale","acquired":false,"shares":22986,"price":20.0136,"value":460032.6096,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"A portion of the shares were sold to satisfy the exercise price and tax obligations relating to the acquisition of the shares in connection with the stock option exercise."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":100800,"source":{"system":"sec-edgar","filing":"0001209191-21-014873","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919121014873/doc4.xml","form_type":"4"}},{"id":2829196,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":135379,"kind":"person","name":"Jones Aranthan II","position":1,"cik":"0001785894","reported_name":"Jones Aranthan II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2021-02-26T22:17:02.000Z","date":"2021-02-24","kind":"exercise","acquired":true,"shares":22499,"price":12.27,"value":276062.73,"ownership":{"direct":true},"balance_after":123786,"source":{"system":"sec-edgar","filing":"0001209191-21-014873","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919121014873/doc4.xml","form_type":"4"}},{"id":2829195,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":135379,"kind":"person","name":"Jones Aranthan II","position":1,"cik":"0001785894","reported_name":"Jones Aranthan II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2021-02-26T22:17:02.000Z","date":"2021-02-24","kind":"grant","acquired":true,"shares":25800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (\"RSU\"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest."}],"balance_after":101287,"source":{"system":"sec-edgar","filing":"0001209191-21-014873","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919121014873/doc4.xml","form_type":"4"}},{"id":3057034,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":135379,"kind":"person","name":"Jones Aranthan II","position":1,"cik":"0001785894","reported_name":"Jones Aranthan II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2020-08-14T20:39:37.000Z","date":"2020-08-12","kind":"sale","acquired":false,"shares":7200,"price":11.8081,"value":85018.32,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.80 to $11.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4."}],"balance_after":75487,"source":{"system":"sec-edgar","filing":"0001209191-20-046804","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919120046804/doc4.xml","form_type":"4"}},{"id":3073887,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":135379,"kind":"person","name":"Jones Aranthan II","position":1,"cik":"0001785894","reported_name":"Jones Aranthan II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2020-07-30T00:17:48.000Z","date":"2020-07-27","kind":"sale","acquired":false,"shares":7313,"price":10.6155,"value":77631.1515,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.48 to $10.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":82687,"source":{"system":"sec-edgar","filing":"0001209191-20-043998","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919120043998/doc4.xml","form_type":"4"}},{"id":3240817,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":135379,"kind":"person","name":"Jones Aranthan II","position":1,"cik":"0001785894","reported_name":"Jones Aranthan II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-02-28T23:02:37.000Z","date":"2020-02-26","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests with respect to 25% of the underlying shares on February 26, 2021, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date."}],"balance_after":70000,"derivative":{"exercise_price":11.32,"expiration_date":"2030-02-25","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-20-014126","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919120014126/doc4.xml","form_type":"4"}},{"id":3240816,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":135379,"kind":"person","name":"Jones Aranthan II","position":1,"cik":"0001785894","reported_name":"Jones Aranthan II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp. Affairs Officer"}}],"security":"Common Stock","published_at":"2020-02-28T23:02:37.000Z","date":"2020-02-26","kind":"grant","acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (\"RSU\"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2021, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest."}],"balance_after":90000,"source":{"system":"sec-edgar","filing":"0001209191-20-014126","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919120014126/doc4.xml","form_type":"4"}}]}